# Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

> **NCT05947448** · — · UNKNOWN · sponsor: **Hasten Biopharmaceutical Co., Ltd.** · enrollment: 1215 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Azilsartan Medoxomil Potassium Tablet
- **DRUG:** Nifedipine Sustained -release Tablets
- **DRUG:** Levoamlodipine Maleate Table

## Key facts

- **NCT ID:** NCT05947448
- **Lead sponsor:** Hasten Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-22
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 1215 (ESTIMATED)
- **Last updated:** 2024-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947448, "Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05947448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*